Pro-Change has completed a Phase 2 NIH Small Business Innovation Research (SBIR) grant for Depression Prevention.
Nine hundred and two adults at risk for depression were recruited from primary care waiting rooms and by telephone. The treatment group received a stage-based manual and an individualized printed report in the mail at baseline, and additional individualized reports at 1 and 3 months follow-up. The treatment and control groups were assessed by phone at 0 and 9 months. At nine months with individuals who were in a pre-Action stage for depression prevention at baseline, treatment group participants were significantly more likely than controls to experience a clinically significant reduction in depression (37% vs. 17%, respectively), to be in the Action or Maintenance stage for depression prevention (70% vs. 55% respectively), and to be taking antidepressant medication if prescribed (71% vs. 50%). Among study participants who were in the Action or Maintenance stage at baseline, the intervention prevented the onset of depression (11% of treatment participants vs. 19% of control participants experienced a new episode of Major Depression during the follow-up period).